205 related articles for article (PubMed ID: 17452421)
1. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
2. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.
Carroll FI; Abraham P; Gong PK; Pidaparthi RR; Blough BE; Che Y; Hampton A; Gunnell M; Lay JO; Peterson EC; Owens SM
J Med Chem; 2009 Nov; 52(22):7301-9. PubMed ID: 19877685
[TBL] [Abstract][Full Text] [Related]
3. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.
Peterson EC; Gentry WB; Owens SM
Adv Pharmacol; 2014; 69():107-27. PubMed ID: 24484976
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
6. Development of murine monoclonal antibodies to methamphetamine and methamphetamine analogues.
Danger Y; Gadjou C; Devys A; Galons H; Blanchard D; Folléa G
J Immunol Methods; 2006 Feb; 309(1-2):1-10. PubMed ID: 16412457
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine.
Celikel R; Peterson EC; Owens SM; Varughese KI
Protein Sci; 2009 Nov; 18(11):2336-45. PubMed ID: 19760665
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites.
Peterson EC; Celikel R; Gokulan K; Varughese KI
PLoS One; 2013; 8(12):e82690. PubMed ID: 24349338
[TBL] [Abstract][Full Text] [Related]
9. Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.
Thakkar S; Nanaware-Kharade N; Celikel R; Peterson EC; Varughese KI
Sci Rep; 2014 Jan; 4():3673. PubMed ID: 24419156
[TBL] [Abstract][Full Text] [Related]
10. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.
Laurenzana EM; Hendrickson HP; Carpenter D; Peterson EC; Gentry WB; West M; Che Y; Carroll FI; Owens SM
Vaccine; 2009 Nov; 27(50):7011-20. PubMed ID: 19800446
[TBL] [Abstract][Full Text] [Related]
11. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a novel conjugated methamphetamine vaccine.
Kamal Hossain M; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccine; 2022 Sep; 40(41):5882-5891. PubMed ID: 36041942
[TBL] [Abstract][Full Text] [Related]
13. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
Clemens KJ; McGregor IS; Hunt GE; Cornish JL
Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
[TBL] [Abstract][Full Text] [Related]
14. Highly specific anti-estradiol antibodies: structural characterisation and binding diversity.
Monnet C; Bettsworth F; Stura EA; Le Du MH; Ménez R; Derrien L; Zinn-Justin S; Gilquin B; Sibaï G; Battail-Poirot N; Jolivet M; Ménez A; Arnaud M; Ducancel F; Charbonnier JB
J Mol Biol; 2002 Jan; 315(4):699-712. PubMed ID: 11812141
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines.
Carroll FI; Blough BE; Pidaparthi RR; Abraham P; Gong PK; Deng L; Huang X; Gunnell M; Lay JO; Peterson EC; Owens SM
J Med Chem; 2011 Jul; 54(14):5221-8. PubMed ID: 21682289
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of monoclonal antibodies against aflatoxins: a possible explanation for the highest sensitivity.
Li X; Li P; Zhang Q; Li Y; Zhang W; Ding X
Anal Chem; 2012 Jun; 84(12):5229-35. PubMed ID: 22548609
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
[TBL] [Abstract][Full Text] [Related]
19. Overview of amphetamine-type stimulant mortality data--UK, 1997-2007.
Schifano F; Corkery J; Naidoo V; Oyefeso A; Ghodse H
Neuropsychobiology; 2010; 61(3):122-30. PubMed ID: 20110737
[TBL] [Abstract][Full Text] [Related]
20. Optimization of a methamphetamine conjugate vaccine for antibody production in mice.
Stevens MW; Gunnell MG; Tawney R; Owens SM
Int Immunopharmacol; 2016 Jun; 35():137-141. PubMed ID: 27039212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
